Low prevalence of antibodies to cyclic citrullinated peptide in Patients with inflammatory bowel disease regardless of the presence of arthritis

European Journal of Gastroenterology and Hepatology

Volumn 22, Issue 6, 2010, Pages 705-709

  Papamichael, Konstantinos ^a   Tsirogianni, Alexandra ^b   Papasteriades, Chryssa ^b   Mantzaris, Gerassimos J ^a  

^a A' Gastroenterology Clinic   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

Author keywords

Anti cyclic citrullinated peptide; Arthritis; Crohn's disease; Infliximab; Ulcerative colitis

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; INFLIXIMAB;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTHRITIS; ARTICLE; COMORBIDITY; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SEROPREVALENCE; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; COLITIS, ULCERATIVE; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; SEROEPIDEMIOLOGIC STUDIES; YOUNG ADULT;

EID: 77951896078     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32832e2bc4     Document Type: Article

References (28)

1. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population based study. Am J Gastroenterol 2001; 96: 1116-1122.
2. De Vos M. Review article: joint involvement in inflammatory bowel disease. Aliment Pharmacol Ther 2004;20 (Suppl 4) : 36-42.
3. Su CG, Judge TA, Lichtenstein GR. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Clin North Am 2002; 31: 307-327.
4. Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998; 42: 387-391.
5. Roussomoustakaki M, Satsangi J, Welsh K, Louis E, Fanning G, Targan S, et al. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology 1997; 112: 1845-1853.
6. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2006; 65: 845-851.
7. Zendman AJ, van Venrooij WJ, Pruijn GJ. Use and significance of anti-CCP autoantibodies in rheumatoid arthritis. Rheumatology (Oxf) 2006; 45: 20-25.
8. Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van't Hof M, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000; 43: 1831-1835.
9. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004; 50: 380-386.
10. Vander Cruyssen B, Hoffman IE, Zmierczak H, Van den Berghe M, Kruithof E, De Rycke L, et al. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis 2005; 64: 1145-1149.
11. Hromadnikova I, Stechova K, Pavla V, Hridelova D, Houbova B, Voslarova S, et al. Anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis. Autoimmunity 2002; 35: 397-401.
12. Salvador G, Gomez A, Vinas O, Ercilla G, Canete JD, Munoz-Gomez J, Sanmarti R. Prevalence and clinical significance of anti-cyclic citrullinated peptide and antikeratin antibodies in palindromic rheumatism. An abortive form of rheumatoid arthritis? Rheumatology 2003; 42: 972-975.
13. Valesini G, Iannuccelli C, Marocchi E, Pascoli L, Scalzi V, Di Franco M. Biological and clinical effects of anti-TNFalpha treatment. Autoimmun Rev 2007; 7: 35-41.
14. Braun-Moscovici Y, Markovits D, Zinder O, Schapira D, Rozin A, Ehrenburg M, et al. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis. J Rheumatol 2006; 33: 497-500.
15. Siemanowski B, Regueiro M. Efficacy of infliximab for extraintestinal manifestations of inflammatory bowel disease. Curr Treat Options Gastroenterol 2007; 10: 178-184. (Pubitemid 46938927)
16. Atzeni F, Turiel M, Capsoni F, Doria A, Meroni P, Sarzi-Puttini P. Autoimmunity and anti-TNF-alpha agents. Ann N Y Acad Sci 2005; 1051: 559-569.
17. Stange EF, Travis SP, Vermeire S, Beglinger C, Kupcinkas L, Geboes K, et al. (European Crohn's and Colitis Organisation) European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006; 55 (Suppl 1) : i1-i15.
18. Kornbluth A, Sachar DB. (Practice Parameters Committee of the American College of Gastroenterology) Ulcerative colitis practice guidelines in adults (update) : American college of gastroenterology, practice parameters committee. Am J Gastroenterol 2004; 99: 1371-1385.
19. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-753.
20. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-444.
21. Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992; 87: 971-976.
22. Van Bodegraven AA, Pena AS. Treatment of extraintestinal manifestations in inflammatory bowel disease. Curr Treat Options Gastroenterol 2003; 6: 201-212.
23. Struyf S, Noppen S, Loos T, Mortier A, Gouwy M, Verbeke H, et al. Citrullination of CXCL12 differentially reduces CXCR4 and CXCR7 binding with loss of inflammatory and anti-HIV-1 activity via CXCR4. J Immunol 2009; 182: 666-674.
24. Makrygiannakis D, af Klint E, Lundberg IE, Löfberg R, Ulfgren AK, Klareskog L, Catrina AI. Citrullination is an inflammation-dependent process. Ann Rheum Dis 2006; 65: 1219-1222.
25. Vossenaar ER, Zendman AJ, van Venrooij WJ. Citrullination, a possible functional link between susceptibility genes and rheumatoid arthritis. Arthritis Res Ther 2004; 6: 1-5.
26. Vossenaar ER, van Venrooij WJ. Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis. Arthritis Res Ther 2004; 6: 107-111.
27. Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A, Valesini G. Decrease of anticyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 2004; 63: 1218-1221.
28. Koutroubakis IE, Karmiris K, Bourikas L, Kouroumalis EA, Drygiannakis I, Drygiannakis D. Antibodies against cyclic citrullinated peptide (CCP) in inflammatory bowel disease patients with or without arthritic manifestations. Inflamm Bowel Dis 2007; 13: 504-505.